Evidence map›Paper›PMID 31358572›Full record

ReviewPractical neurology2020

Speech and language therapy approaches to managing primary progressive aphasia.

Anna Volkmer, Emily Rogalski, Maya Henry, Cathleen Taylor-Rubin, Leanne Ruggero, Rebecca Khayum, Jackie Kindell, Maria Luisa Gorno-Tempini, Jason D Warren, Jonathan D Rohrer

Registry-linked trialAbstract readReview
In one paragraph

Review in Practical neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06739967 (Speech and Language-Tailored Interventions for People With Primary Progressive Aphasia), which is not on this map. Cited by 52 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06739967 recruitingnot on this mapstarted 2024, after this paper: background citation

Speech and Language-Tailored Interventions for People With Primary Progressive Aphasia

TypeobservationalSponsorIstituti Clinici Scientifici Maugeri SpARan2024 to 2026Enrolled30ConditionsPrimary Progressive Aphasia(PPA)ArmsBehavioral Treatment
3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Anna VolkmerDivision of Psychology and Language Sciences, University College London, London, UK.
Emily RogalskiMesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern University (NU) Feinberg School of Medicine, Chicago, Illinois, USA.
Maya HenryDepartment of Communication Sciences and Disorders, University of Texas at Austin, Austin, Texas, USA.
Cathleen Taylor-RubinDepartment of Cognitive Science, Macquarie University, Sydney, New South Wales, Australia.
Leanne RuggeroDepartment of Cognitive Science, Macquarie University, Sydney, New South Wales, Australia.
Rebecca KhayumMesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern University (NU) Feinberg School of Medicine, Chicago, Illinois, USA.
Jackie KindellDivision of Nursing, Midwifery and Social Work, University of Manchester, Manchester, UK.
Maria Luisa Gorno-TempiniDepartment of Neurology, Memory and Aging Center, University of California San Francisco, San Francisco, California, USA.
Jason D WarrenDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.
Jonathan D RohrerDementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK j.rohrer@ucl.ac.uk.

Funding

TDP-43 Loss-of-Function: Biology to BiomarkersP01AG019724 · NIA · UNIVERSITY OF PENNSYLVANIA · PI Jennifer Merrilees · 2002 to 2026
$67.2M
Neuropathology CoreP30AG013854 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ROGALSKI, EMILY J · 1996 to 2020
$28.9M
Communication Bridge: Optimizing an evidence-based intervention for individuals with primary progressive aphasiaR01AG055425 · NIA · UNIVERSITY OF CHICAGO · PI EMILY J ROGALSKI, Angela Christine Roberts · 2017 to 2026
$14.8M
Progressive Aphasia Cognition Anatomy and ProgressionR01NS050915 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARIA LUISA GORNO TEMPINI · 2004 to 2026
$11.0M
Language in Primary Progressive AphasiaR01DC008552 · NIDCD · NORTHWESTERN UNIVERSITY AT CHICAGO · PI MESULAM, MAREK-MARSEL M · 2007 to 2021
$8.5M
Connectomic imaging in familial and sporadic frontotemporal degenerationU01AG052943 · NIA · UNIVERSITY OF PENNSYLVANIA · PI GORNO TEMPINI, MARIA LUISA, GROSSMAN, MURRAY · 2016 to 2019
$5.9M
Determinants of neurodegenerative decline in the aphasic variant of Alzheimer's diseaseR01AG056258 · NIA · UNIVERSITY OF CHICAGO · PI ROGALSKI, EMILY J · 2017 to 2022
$4.1M
Dynamic Brain Imaging of Speech in Primary Progressive AphasiaR01NS100440 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARIA LUISA GORNO TEMPINI, John Francis Houde · 2017 to 2026
$3.6M
Establishing Evidence-based Treatment for Speech and Language in Primary Progressive AphasiaR01DC016291 · NIDCD · UNIVERSITY OF TEXAS AT AUSTIN · PI HENRY, MAYA · 2017 to 2021
$3.3M
Communication Bridge: A person-centered Internet-based intervention for individuals with primary progressive aphasiaR56AG055425 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ROBERTS, ANGELA CHRISTINE, ROGALSKI, EMILY J · 2022 to 2022
$2.2M
Training program in the neurology of language and neurodegenerative aphasiasK24DC015544 · NIDCD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GORNO TEMPINI, MARIA LUISA · 2016 to 2025
$1.9M
Determinants of Neurodegenerative Decline in Primary Progressive AphasiaR01NS075075 · NINDS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ROGALSKI, EMILY J · 2012 to 2016
$1.7M
Medical Research Council MR/M008525/1NIA NIH HHS P01 AG019724NIA NIH HHS P30 AG013854NIA NIH HHS R01 AG055425NIA NIH HHS R01 AG056258NIA NIH HHS R56 AG055425NIA NIH HHS U01 AG052943NIDCD NIH HHS K24 DC015544NIDCD NIH HHS R01 DC008552NIDCD NIH HHS R01 DC016291NIDCD NIH HHS R03 DC013403NINDS NIH HHS R01 NS050915NINDS NIH HHS R01 NS075075NINDS NIH HHS R01 NS100440NINDS NIH HHS R56 NS050915
6 · The paper itself

Abstract

The term primary progressive aphasia (PPA) describes a group of neurodegenerative disorders with predominant speech and language dysfunction as their main feature. There are three main variants - the semantic variant, the nonfluent or agrammatic variant and the logopenic variant - each with specific linguistic deficits and different neuroanatomical involvement. There are currently no curative treatments or symptomatic pharmacological therapies. However, speech and language therapists have developed several impairment-based interventions and compensatory strategies for use in the clinic. Unfortunately, multiple barriers still need to be overcome to improve access to care for people with PPA, including increasing awareness among referring clinicians, improving training of speech and language therapists and developing evidence-based guidelines for therapeutic interventions. This review highlights this inequity and the reasons why neurologists should refer people with PPA to speech and language therapists.

Indexed as

Disease ManagementAphasia, Primary ProgressiveHumansLanguage TherapySpeech Therapyaphasiafrontotemporal dementiaprimary progressive aphasiaspeech therapy

Identifiers

PMID31358572
PMCPMC6986989

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.